1. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial
   Jian-wei Li et al, 2019, Breast Cancer Research and Treatment CrossRef
2. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
   Yanyun Gao et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef
3. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
   Rafael Caparica et al, 2020, Expert Review of Anticancer Therapy CrossRef